Packaging
to a successful conclusion. If a trial fails because of flawed labels, which can be easily avoided, then it could prove to be a very expensive error. Cynthia Tanguay, who was the lead author of a study by researchers from the Practical Pharmacy Research Unit at the Sainte-Justine Hospital Center in Montreal, (investigational drug labelling variability), says that labels vary greatly in the reliability of the information they contain. She believes that international standards are needed to ensure all countries comply, and that there is a consistent standard that’s met. She also says: “With trials being conducted in multiple countries, study drugs often have labels that would work for many different countries, so they contain many pages (the label is often a multiple-page/multiple-language leaflet attached to a container), and the information can be hard to find.” “Some sponsors differentiate their product with various strategies, but there is no standardisation across different companies,” added Tanguay, who is also pharmacy research coordinator at the Centre Hospitalier Universitaire (CHU) Sainte-Justine.
Better safe than sorry
The Montreal study found that the lack of international regulations covering drug labelling on investigational drugs used in clinical trials, meant that errors were made at different stages in their production and distribution. Mistakes in the labelling could be introduced, for example, at the point of dispensing, or when the medication is being stored prior to distribution. The researchers found that errors on labels included no expiry date and storage instructions missing. There was also a variety of different presentations on labels, such as bold characters and empty space to make them easier to read, which were often not used. Tanguay explains how new international guidelines could be introduced: “Canada has distinct regulatory requirements for clinical trial drugs labelling, and this is independent from the ICH (International Council on Harmonisation) GCP (Good Clinical Practices) requirement. “The ICH GCP are adopted by most countries in order to standardise the way clinical trials are conducted. Labelling could be addressed there. I’m not an expert in other countries legislation, but I’m sure that they also have distinct regulations which explain why sponsors are using labels with so many pages and information in them,” she continues. “Other organisations not specific to clinical trials such as ISMP (Institute for Safe Medical Practices) exist to reduce the risk of errors with drugs, and their standards could be useful for clinical trials.
Clinical Trials Insight /
www.worldpharmaceuticals.net
Recommendations from the ISMP for improvements include:
■ Select and approve a standardised identifier for a new investigational drug that is unique and distinctive from other investigational drugs and the protocol number.
■ Assign a generic drug name as early as possible, preferably before the investigational drug begins Phase II trials.
■ Perform a risk assessment on the new investigational drug’s name, labelling, and packaging to identify any potential risks that might result in medication errors.
■ Never refer to an investigational drug solely by its protocol number, IRB number, study acronym or title, investigator’s name, or other common name.
■ Package oral investigational drugs in patient-ready unit-of-use packaging (for example, no large bulk bottles of 1,000 capsules that need to be repackaged for multiple patients, but rather patient-specific bottles of capsules containing exactly one-month’s supply).
■ Package parenteral investigational medications in vials/containers in the size and volume that best corresponds to the dosing, so that dozens of vials/ containers or serial dilutions/aliquots are not required for single doses.
■ For label text on product containers, use a font size of eight or larger, and make the drug name and strength most prominent. Use tall man letters to help distinguish look-alike names. Avoid extraneous information and known error- prone abbreviations and dose expressions.
Source: ISMP
I’m thinking for example of ‘tall-man lettering’, which is seldom found on clinical trial labels.” Matthew Grissinger, director of education at ISMP in the US, agrees that some guidelines are much needed.
“There are no regulations that dictate the labelling, and that is a pretty fundamental problem,” he says. A clinical trial may be testing a fantastic drug, but if there is an error caused by poor labelling then we may never know how good it is. Grissinger points to a public meeting in May last year organised by the US Food and Drug Administration, which discussed error risks with investigational drug container labels, as a cause of optimism that the problems are being addressed.
“There are no regulations that dictate the labelling, and that is a pretty fundamental problem.”
Matthew Grissinger
Pharmacists and researchers, who contributed to the meeting, highlighted a list of labelling risk areas, including missing drug names, missing or hard-to- find information on the strength of IMPs, small font sizes, and unsafe abbreviations and dose expressions. A representative from the FDA told the meeting the purpose was to hear about the experience of professionals working in clinical trials. “We have received medication error reports associated with investigational drugs, and we are aware of global regulatory differences for labelling investigational drugs and medication errors. And we understand that the situation can be improved,” he said.
49
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53
